Onswik (insulin efsitora alfa-gobe)

Where it stands

The records show Onswik (insulin efsitora alfa-gobe), from Eli Lilly And Co, as approved in the US. The FDA approval is dated 2026-09-23 under BLA761408, and the product is described as an injectable.

In the EU, the records show a CHMP positive opinion on 2026-06-25, with Eli Lilly Nederland B.V. named as the applicant. No official European Commission decision appears in the records. The only EC entry is an estimated decision date of 2026-08-31, calculated as the CHMP opinion plus 67 days, the standard Commission decision period. The records state that this is not an official date, so the EU authorisation status should be treated as unconfirmed until the Commission decision is verified.

The record header shows the CHMP opinion date as blank, although the milestone list gives 2026-06-25. The therapeutic area and indication fields are also empty, so this analysis cannot say what the product is authorised to treat.

Regulatory pathway and designations

The only designation recorded is "Biosimilar", and the FDA milestone describes the product as a biosimilar approved under BLA761408. A biosimilar approval would normally rely on a comparison with a named reference product. The records do not identify any reference product, and they give no detail on the data package or on any interchangeability status.

Readers should confirm the biosimilar label against the FDA approval documents before relying on it. The records are the only basis here, and they do not explain how the label fits with the product's name and description.

The records show an EU route through the centralised procedure, in which a CHMP opinion is followed by a Commission decision, typically within about 67 days. In the records, the CHMP opinion came before the US approval. The EU applicant entity is Eli Lilly Nederland B.V., while the US entry names Eli Lilly And Co.

Safety and pharmacovigilance

The records contain no safety information. They give no labelled warnings, risk management plan content, post-marketing commitments, REMS, or adverse event data, so no safety assessment can be made from them.

What to watch

First, confirm whether the European Commission has issued its decision. The 2026-08-31 date is only an estimate, and the records show no confirmed outcome.

Second, obtain the FDA approval documents and labelling. They should clarify the indication, the biosimilar basis and reference product, any interchangeability determination, and any post-marketing requirements. None of these are in the records.

Third, once the EU product information and any risk management plan are published, compare them with the US label for differences in indication, warnings and pharmacovigilance obligations.